Horizon Discovery Group plc Board Change (5496G)
March 02 2018 - 7:00AM
UK Regulatory
TIDMHZD
RNS Number : 5496G
Horizon Discovery Group plc
02 March 2018
Horizon Discovery Group plc
Board Change
Cambridge, UK, 2 March 2018: Horizon Discovery Group plc (LSE:
HZD) ("Horizon" or "the Group"), a global leader in gene editing
and gene modulation technologies, announces that, further to the
statement issued on 20 February 2018 in which it was noted that
Darrin Disley had decided to step down as CEO, Darrin Disley is no
longer a Board Director of the Group as of today's date.
Horizon's Board consists of the following representatives:
Dr Ian Gilham
Executive Chairman
Richard Vellacott
Interim Chief Executive Officer and Chief Financial Officer
Dr Jonathan Milner
Non-Executive Director
Mrs Susan Searle
Non-Executive Director
Dr Susan Galbraith
Non-Executive Director
Dr Vishal Gulati
Non-Executive Director
Grahame Cook
Non-Executive Director
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Richard Vellacott, Interim Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, Inc., its functional genomics platform comprising
gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUUSARWBAORAR
(END) Dow Jones Newswires
March 02, 2018 07:00 ET (12:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024